Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Karuna Therapeutics Inc (NQ: KRTX )

196.88 +0.80 (+0.41%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 27, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Karuna Therapeutics Inc

< Previous 1 2 3 4 Next >
SVB Likes This 'Novel Antipsychotic'-Focused Stock
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 14, 2022
Upgrades 
Via Benzinga
JMP Views Positive Phase 3 Data Equivalent To 'Schizophrenia Blockbuster' For This Stock
 
Via Benzinga
Analyst Ratings for Karuna Therapeutics
Analysts have provided the following ratings for Karuna Therapeutics (NASDAQ:KRTX) within the last quarter: 
Via Benzinga
Analyst Ratings for Karuna Therapeutics
Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
The Daily Biotech Pulse: AstraZeneca Goes Shopping, TYME Technologies & Syros Pharma Merger, FDA Clears Vertex Pharma's Stem Cell-Based Diabetes Therapy Study
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Karuna Therapeutics, Inc. with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Karuna Therapeutics to Present at Upcoming Investor Conferences
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics: Q1 Earnings Insights
Karuna Therapeutics (NASDAQ:KRTX) reported its Q1 earnings results on Thursday, May 5, 2022 at 06:00 AM. Here's what investors need to know about the announcement. 
Via Benzinga
Mizuho Sees Compelling Risk/Reward For This Schizophrenia Stock Despite Recent Weakness
Yesterday, Karuna Therapeutics Inc (NASDAQ: KRTX) highlighted progress across the ongoing and planned clinical programs of KarXT, with a primary focus on the planned Phase 3 program evaluating KarXT... 
Via Benzinga
Karuna Therapeutics to Host Virtual Event Highlighting Clinical Program for Psychosis in Alzheimer’s Disease
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Reports First Quarter 2022 Financial Results and Provides General Business Update
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Present at the 2022 RBC Capital Markets Global Healthcare Conference
From Karuna Therapeutics, Inc.
Via Business Wire
What 4 Analyst Ratings Have To Say About Karuna Therapeutics
Karuna Therapeutics (NASDAQ:KRTX) has observed the following analyst ratings within the last quarter: 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 31, 2022
Upgrades 
Via Benzinga
Amid Russia's Invasion On Ukraine, Karuna Therapeutics Withdraws Guidance On Late-Stage Schizophrenia Trial
According to an SEC filing, Karuna Therapeutics Inc (NASDAQ: KRTX) is withdrawing its prior guidance for the timing of topline data for its Phase 3 EMERGENT-3 trial... 
Via Benzinga
Karuna Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides General Business Update
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
From Karuna Therapeutics, Inc.
Via Business Wire
This Metaverse Stock Will Be Featured On 'Mad Money' Wednesday Night
Unity Software Inc (NYSE:U) CEO John Riccitiello 
Via Benzinga
Karuna Therapeutics Appoints Charmaine Lykins as Chief Commercial Officer
From Karuna Therapeutics, Inc.
Via Business Wire
Week In Review: Zai Lab Announces Two In-Licensings With Total Value Of $800 Million
Shanghai Zai Lab announced two major in-licensings: a $615 million deal for two cancer drugs from Blueprint Medicines and a $187 million agreement for a psychiatric drug from Karuna Therapeutics. 
Via Talk Markets
Why Karuna Therapeutics Stock Tumbled This Week
Investors apparently weren't thrilled by the company's licensing agreement with Zai Lab. 
Via The Motley Fool
Zai Lab Inks Back To Back Licensing Agreements For Cancer And Psychiatric Candidates
Zai Lab Limited (NASDAQ: ZLAB) and Blueprint Medicines Corporation (NASDAQ: BPMC) have announced an exclusive collaboration and license agreement in... 
Via Benzinga
76 Biggest Movers From Yesterday
Gainers Expensify, Inc. (NASDAQ: EXFY) jumped 52.1% to settle at $41.06 on Wednesday after the company priced its IPO at $27 per share. RenovoRx, Inc. (NASDAQ: RNXT) shares... 
Via Benzinga
Topics Initial Public Offering
Exposures Securities Market
PureTech Founded Entity Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
From PureTech Health plc
Via Business Wire
Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercialization of KarXT in Greater China
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics to Present at Upcoming Investor Conferences
From Karuna Therapeutics, Inc.
Via Business Wire
Karuna Therapeutics Reports Third Quarter 2021 Financial Results and Provides General Business Update
From Karuna Therapeutics, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2021
Upgrades For Cabot Oil & Gas Corp (NYSE:COG),... 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.